Quick Takeaways:
- Gallant reported positive pilot study results for IV uterine-derived mesenchymal stromal cell (UMSC) therapy in cats with Feline Osteoarthritis, showing significant improvements in pain and quality of life vs. placebo
- Trial showed that at 3 months, treated cats had better outcomes vs placebo, with improvements in CSOM QoL (76.2% vs 36.4%), owner-reported QoL (81% vs 36.4%), vet-assessed pain (81% vs 45.5%), and overall QoL per vets (60% vs 20%)
- The US FDA Center for Veterinary Medicine granted eligibility for the expanded conditional approval pathway, accelerating development of a potential disease-modifying treatment in an underserved feline segment
Why It Matters?
Gallant’s positive UMSC pilot data and FDA CVM’s expanded conditional approval eligibility together position this program as a potential first‑in‑class, disease‑modifying biologic in an almost empty feline OA toolbox.
By showing up to 81% improvement on owner and vet assessments vs placebo and confirming good tolerability, Gallant now has a credible efficacy signal to justify accelerated investment, de‑risk partnering or distribution deals, and help define a premium, regenerative segment in senior‑cat pain management where current NSAID options are limited and largely symptomatic.
Source: PRnewswire
